Figure 4.

SMU‐Z1 increases splenocyte proliferation, CD8⁺/CD4⁺ ratio, and TLR2 expression. A) SMU‐Z1 treatment accelerated splenocyte proliferation at different concentrations. B) Time kinetics of SMU‐Z1 stimulated primary splenocyte proliferation at 5 × 10⁻⁶ m. Cell proliferation was tested by measuring CCK8 absorbance at 450 nm at different time intervals. C) Percentages of CD19⁺ B cells present within splenocytes were determined by flow cytometry at various time points after treatment with PBS, 5 µg Pam₃CSK₄ (Pam3), or 0.1 mg of SMU‐Z1 in C57BL/6 mice. D) Representative graphs of CD4⁺ and CD8⁺ T cells from PBS, Pam₃CSK₄ (Pam3), or SMU‐Z1‐treated mice. The percentage of CD8⁺ and ratio of CD8⁺/CD4⁺ T cells increased after treatment with SMU‐Z1. E) Percentage of TLR2 positive cells (CD3⁺CD8⁺TLR2⁺) in the spleen. Results shown are average values from three independent experiments, and the data are presented as mean ± SD. *, p < 0.01; **, p < 0.001 compared to the control group.